Goldman Sachs analysts initiated coverage on Doximity (NYSE:DOCS) with a Neutral rating and a price target on the stock of $58. The evaluation reflects a balanced outlook, acknowledging the company’s strong market position and growth potential while noting limited upside at current valuation levels. Doximity operates in an attractive end-market, holding a leadership position that supports its long-term growth prospects. Goldman Sachs projected sustained industry performance of 6-7% annually, with Doximity expected to outpace the market, driving a 9-10% compound annual revenue growth rate (CAGR) from fiscal 2025 through fiscal 2028. The company’s ability to expand its core customer base and achieve its fiscal 2025 guidance, as well as outer-year revenue forecasts, was further reinforced by its strong performance in the second quarter of fiscal 2025. In addition to revenue growth, Goldman Sachs highlighted a clear trajectory for EBITDA margin expansion. The analysts forecasted an increase of 180 basis points in margins from fiscal 2025 to fiscal 2028, reflecting operational efficiencies and strong execution. While Doximity’s fundamentals remain robust, the Neutral rating suggests that current valuation levels already account for much of its growth potential, leaving limited room for near-term upside.
D oximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical manufacturers and healthcare systems.